ATE377606T1 - Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren - Google Patents

Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren

Info

Publication number
ATE377606T1
ATE377606T1 AT98930536T AT98930536T ATE377606T1 AT E377606 T1 ATE377606 T1 AT E377606T1 AT 98930536 T AT98930536 T AT 98930536T AT 98930536 T AT98930536 T AT 98930536T AT E377606 T1 ATE377606 T1 AT E377606T1
Authority
AT
Austria
Prior art keywords
receptors
protein coupled
coupled receptors
cyclic antagonists
protein
Prior art date
Application number
AT98930536T
Other languages
German (de)
English (en)
Inventor
David Fairlie
Stephen Taylor
Angela Finch
Allan Wong
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Application granted granted Critical
Publication of ATE377606T1 publication Critical patent/ATE377606T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
AT98930536T 1997-06-25 1998-06-25 Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren ATE377606T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO7550A AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist

Publications (1)

Publication Number Publication Date
ATE377606T1 true ATE377606T1 (de) 2007-11-15

Family

ID=3801840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930536T ATE377606T1 (de) 1997-06-25 1998-06-25 Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren

Country Status (11)

Country Link
US (5) US6821950B1 (cg-RX-API-DMAC7.html)
EP (1) EP1017713B1 (cg-RX-API-DMAC7.html)
JP (1) JP4686696B2 (cg-RX-API-DMAC7.html)
AT (1) ATE377606T1 (cg-RX-API-DMAC7.html)
AU (2) AUPO755097A0 (cg-RX-API-DMAC7.html)
CY (1) CY1107133T1 (cg-RX-API-DMAC7.html)
DE (1) DE69838678T2 (cg-RX-API-DMAC7.html)
DK (1) DK1017713T3 (cg-RX-API-DMAC7.html)
ES (1) ES2294816T3 (cg-RX-API-DMAC7.html)
PT (1) PT1017713E (cg-RX-API-DMAC7.html)
WO (1) WO1999000406A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPQ339899A0 (en) 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
ES2353077T3 (es) 2000-08-10 2011-02-25 Mitsubishi Tanabe Pharma Corporation Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos.
CN1474803B (zh) 2000-09-14 2012-11-21 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
US8524862B2 (en) 2002-03-19 2013-09-03 Cincinnati Children's Hospital Medical Center Muteins of C5a anaphylatoxin and methods of inhibiting C5a
US20040014782A1 (en) * 2002-03-29 2004-01-22 Krause James E. Combination therapy for the treatment of diseases involving inflammatory components
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002950657A0 (en) 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
AU2003266858B2 (en) * 2002-10-11 2006-09-14 Vast Bioscience Pty Limited Classes of compounds that interact with GPCRs
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
WO2004035078A1 (en) * 2002-10-16 2004-04-29 The University Of Queensland Treatment of inflammatory bowel disease
AU2002952129A0 (en) * 2002-10-17 2002-10-31 The University Of Queensland Treatment of hypersensitivity conditions
AU2003902354A0 (en) * 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
AU2003902586A0 (en) * 2003-05-26 2003-06-12 The University Of Queensland Treatment of burns
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
EP1498422A1 (de) * 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
CN101036057A (zh) * 2004-10-04 2007-09-12 阿尔卡米亚有限公司 选择性抑制剂
JP2008526915A (ja) * 2005-01-17 2008-07-24 イエリニ・アクチェンゲゼルシャフト Ｃ５ａ受容体アンタゴニスト
EP1861114B1 (en) * 2005-03-11 2011-02-02 Potentia Pharmaceuticals, Inc. Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
US20110092446A1 (en) * 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
JP2011526738A (ja) * 2008-07-02 2011-10-13 サンゴバン・パフォーマンス・プラスティックス・シェンヌー 枠付き装置、封止材およびその製造方法
BRPI0921237A2 (pt) 2008-11-10 2015-09-22 Alexion Pharma Inc métodos e composições para o tratamento de distúrbios associados ao complemento
EP2525814A4 (en) * 2010-01-22 2013-09-11 Univ Louisville Res Found METHODS OF TREATING OR PREVENTING PERIODONTITIS AND PARODONTIST-RELATED DISEASES
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
EP2588121A4 (en) * 2010-06-29 2013-12-04 Univ Nebraska C5A ANALOGUE AND USE METHOD THEREFOR
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
BR112013033272A2 (pt) 2011-06-22 2020-11-10 Apellis Pharmaceuticals, Inc. composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
WO2014043223A1 (en) * 2012-09-11 2014-03-20 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2014248252A1 (en) * 2013-04-02 2015-10-29 M. Reza Ghadiri Uses of cyclic peptides for treating and preventing atherosclerosis
EP3290922A1 (en) 2013-08-07 2018-03-07 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
FI3359555T3 (fi) 2015-10-07 2024-03-20 Apellis Pharmaceuticals Inc Annostusohjeet
MA45770A (fr) 2016-07-29 2019-06-05 Pfizer Peptides cycliques en tant qu'antagonistes du récepteur c5
JP7128182B2 (ja) 2016-10-27 2022-08-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害におけるＣ５ｂ－９沈着に関するアッセイ
ES2893769T3 (es) 2017-04-03 2022-02-10 Inflarx Gmbh Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
EP3642230A1 (en) 2017-06-23 2020-04-29 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
EP4126222A1 (en) 2020-03-27 2023-02-08 InflaRx GmbH Inhibitors of c5a for the treatment of corona virus infection
CN115667925A (zh) 2020-05-15 2023-01-31 阿雷克森制药公司 使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途
WO2024238421A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of biomarkers for the identification and treatment of complement-mediated disorders
WO2024238422A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5386011A (en) 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
FI962319A7 (fi) * 1993-12-06 1996-06-03 Novartis Ag C5a-reseptorin antagonistit, joilla ei ole olennaista agonistiaktiivis uutta
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis

Also Published As

Publication number Publication date
AU744991B2 (en) 2002-03-07
EP1017713A4 (en) 2002-07-24
US20090203760A1 (en) 2009-08-13
PT1017713E (pt) 2007-12-18
AUPO755097A0 (en) 1997-07-17
US20130005644A1 (en) 2013-01-03
US20060160726A1 (en) 2006-07-20
DE69838678T2 (de) 2008-10-30
HK1029595A1 (en) 2001-04-06
AU8092698A (en) 1999-01-19
ES2294816T3 (es) 2008-04-01
JP4686696B2 (ja) 2011-05-25
EP1017713A1 (en) 2000-07-12
DK1017713T3 (da) 2008-02-11
JP2002508767A (ja) 2002-03-19
DE69838678D1 (de) 2007-12-20
US6821950B1 (en) 2004-11-23
CY1107133T1 (el) 2012-10-24
WO1999000406A1 (en) 1999-01-07
EP1017713B1 (en) 2007-11-07
USRE41287E1 (en) 2010-04-27

Similar Documents

Publication Publication Date Title
ATE377606T1 (de) Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
ATE254456T1 (de) Cannabinoid-rezeptor-antagonisten
EA199900630A1 (ru) Антагонисты рецепторов витронектина
SE9704836D0 (sv) Novel receptor
EA200300663A1 (ru) Антагонисты cxcr3
ATE299494T1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DE60329030D1 (de) Melanocortin-rezeptormodulatoren
PT934310E (pt) N-heterociclicos monociclicos substituidos por tioacido uteis como anti-coagulantes
MY137457A (en) Cyclic peptides having melanocortin-4 receptor agonist activity
YU34898A (sh) Antagonisti ccr-3 receptora
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
ATE344261T1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
EA200201119A1 (ru) Лиганды меланокортиновых рецепторов
EA200200933A1 (ru) Антагонисты рецептора il-8
BR0011122A (pt) Antagonistas de receptor il-8
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
ATE282041T1 (de) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
EP0862627A4 (en) RECEPTOR OF Y-Y5 NEUROPEPTID
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
ATE343634T1 (de) Gaba b-rezeptor-subtypen gaba b-r1c und gaba b-r2 und deren heterodimere
DE50200864D1 (de) Verbundelemente enthaltend bitumen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1017713

Country of ref document: EP